SOURCE: Milestone Scientific, Inc.
LIVINGSTON, NJ--(Marketwire - Nov 8, 2012) - Milestone Scientific Inc. (OTCQB: MLSS), the recognized leader in advanced, computer-controlled injection technologies, and Aseptico Inc., a leading designer and manufacturer of surgical, endodontic, and portable dental equipment that is distributed worldwide, today announced the formation of a strategic alliance, whereby Aseptico will serve as the exclusive distributor of Milestone's Single Tooth Anesthesia System® (STA System) and all related disposable items.
Aseptico and Milestone also announced a joint marketing initiative to drive sales in the United States and Canada. The marketing initiative will include participation in U.S. and Canadian dental shows, as well as pediatric dental shows; an active advertising initiative targeting major dental publications; and direct mailing campaigns to over 150,000 dentists across the U.S. and Canada.
Glenn Kazen, President of Aseptico, stated, "We are excited to partner with Milestone and look forward to aggressively expanding sales of the STA System across the United States and Canada. The STA System offers patients a truly pain free experience and represents the most advanced drug delivery system in the market. The product has mass appeal to the estimated 40 million plus dental phobics in the United States, as well as pediatric patients and adult patients that seek a more pleasurable dental experience. In addition to enhancing the patient experience, the STA System provides distinct benefits to the dentists, including faster onset of profound anesthesia, which allows the dentist to see significantly more patients due to shorter waiting time for onset of anesthesia. Overall, we believe the STA System will resonate extremely well with new and existing dental customers and reinforces our commitment to providing our dental customers with exclusive access to the most advanced and effective products on the market."
Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "Having served the dental market for over 36 years, Aseptico is an ideal partner for Milestone as they currently market their products to over 150,000 dentists across the United States and Canada and have well established sales channels. We see this partnership as a means to rapidly and cost-effectively deepen our penetration of the U.S. and Canadian dental markets. This partnership also allows us to focus greater resources internally on developing new medical applications for our computerized, drug delivery system. We look forward to working closely with the experienced team at Aseptico as we enter the next phase of our growth."
About Milestone Scientific Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering advanced computer-controlled drug delivery technologies for the medical and dental markets and currently sells its award-winning products through a global distribution network serving North and South America, Asia, Africa, Europe and the Middle East. For more information on the STA Single Tooth Anesthesia System® instrument and other innovative Milestone products, please visit the Company's web site found at www.milestonescientific.com.
About Aseptico Inc.
Headquartered in Woodinville, Washington, Aseptico is a leading designer and manufacturer of surgical, endodontic, and portable dental equipment that is distributed worldwide. Aseptico manufactures products in the United States and employs over 100 local staff at the Company's headquarters in the greater Seattle area. Aseptico has an in-house engineering team and develops products to be fully regulatory compliant to US and international manufacturing and safety standards, including FDA Good Manufacturing Practices, ISO 60601-1, and ISO 13485:2003. Aseptico also exports its products to over 125 countries. Additional information is available at: www.aseptico.com.
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2011. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.